Tumor necrosis factor- may contribute to alterations in protein and energy metabolism in children with Crohn's disease suffering from growth disturbance.
Dr Steven Steiner and colleagues from Indiana assessed whether anti-tumor necrosis factor-therapy would reduce protein losses.
The doctors also evaluated whether anti-tumor necrosis factor-therapy would decrease resting energy expenditure.
The team of doctors hypothesized that this effect would be due to decreased proteolysis and increased protein synthesis.
|Supplementation with parenteral nutrition improved protein metabolism|
|Inflammatory Bowel Diseases|
The team evaluated 15 children with active Crohn's disease.
The patients underwent metabolic assessment immediately before and 2 weeks following initial infliximab infusion.
The doctors used 2 independent measures of protein metabolism during fasting and in response to parenteral nutrition.
Energy expenditure, determined by indirect calorimetry, was measured in fasting and parenterally fed states.
Following infliximab therapy, significant reductions in proteolysis were noted in the fasting state, and during parenteral nutrition infusion.
The doctors found that phenylalanine utilization for protein synthesis decreased significantly following infliximab.
The team observed that protein balance was not significantly altered.
The doctors found no significant changes in energy expenditure following infliximab in fasting or parenterally fed states.
Supplementation with parenteral nutrition resulted in significantly decreased proteolysis.
The team of doctors found increased protein synthesis, and improved protein balance compared to the fasting state.
Dr Steiner's team concluded, "Following the initial infliximab infusion in children with Crohn's disease, proteolysis and protein synthesis were significantly reduced in the fasting and parenterally fed states."
"Supplementation with parenteral nutrition resulted in significant improvements in protein metabolism compared to the fasting state both before and after infliximab therapy."